Pfizer Generates Sustainability Concerns Over Patent Expirations While Paying $14.6 Billion in Dividends Over 18 Months

Pfizer has distributed a total of $14.6 billion in dividends over the past 18 months. This substantial payout underscores the company’s robust cash flow and its prioritisation of shareholder returns. Dividends account for a significant portion of the firm’s annual net profit, offering attractive returns to investors while simultaneously increasing pressure on future profitability and cash‑flow generation. The company faces a risk from the impending expiration of patents on key products in its core portfolio. Once patents lapse, generic competitors may enter the market, potentially eroding Pfizer’s revenue streams. The sustainability of Pfizer’s dividend policy hinges on future revenue growth, cash reserves, and ongoing investment in new drug development. Investors are advised to closely monitor the company’s earnings reports and cash‑flow statements. This is not investment advice.